DOI: 10.12890/2026_007493

Tirzepatide-induced gastroparesis with prolonged recovery

Authors

  • Tanuj Diyora Department of Internal Medicine, Dr KNS Memorial Institute of Medical Sciences, Barabanki, India
  • Mian Zia Ur Rehman Department of Internal Medicine, FMH College of Medicine & Dentistry, Lahore, Pakistan
  • Asim Kuli Ogli Department of Pulmonary Medicine, Tbilisi State Medical University, Tbilisi, Georgia

drtanujsmmanagement@gmail.com

Keywords

Tirzepatide, gastroparesis, delayed gastric emptying, glucagon-like peptide-1 (GLP-1) receptor agonist, glucose-dependent insulinotropic polypeptide (GIP) receptor agonist

Abstract

Background: Tirzepatide, a first-in-class dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist, has emerged as a potent agent for the management of type 2 diabetes mellitus (T2DM) and obesity. Delayed gastric emptying is a recognised pharmacological effect of incretin-based therapies; however, frank drug-induced gastroparesis with an unusually prolonged clinical course has been infrequently reported for tirzepatide.
Case description: We describe a 52-year-old man with T2DM and obesity who developed debilitating nausea, recurrent non-bilious vomiting, early satiety, and an 8-kg weight loss over 4 weeks following escalation of tirzepatide to 10 mg weekly. Mechanical obstruction was excluded by upper gastrointestinal endoscopy, and gastric emptying scintigraphy confirmed markedly delayed solid gastric emptying with 58% meal retention at 4 hours. Tirzepatide was discontinued, and treatment with oral metoclopramide and dietary modification was initiated. Despite cessation of the offending agent, symptomatic and objective resolution did not occur until approximately 9 weeks after discontinuation, suggesting a prolonged neuromotor recovery trajectory beyond standard pharmacokinetic expectations.
Conclusion: This case highlights tirzepatide as a cause of clinically significant, potentially long-lasting gastroparesis. Clinicians should recognise that recovery after drug discontinuation may be protracted. Early identification, patient education, and judicious dose escalation are essential safety measures for this increasingly prescribed medication.

View the entire article

Downloads

References

  1. Farzam K, Patel P. Tirzepatide. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing. 2024 [updated 2024 Feb 20; cited 2026 Oct 23]. Available from: https://www.ncbi.nlm.nih.gov/books/NBK595432/.
  2. Coskun T, Sloop KW, Loghin C, Alsina-Fernandez J, Urva S, Clinchard KM, et al. LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: from discovery to clinical proof of concept. Mol Metab. 2018;18:3–14. doi: 10.1016/j.molmet.2018.09.009.
  3. Nauck MA, D’Alessio DA. Tirzepatide, a dual GIP/GLP-1 receptor co-agonist for the treatment of type 2 diabetes with unmatched effectiveness regrading glycaemic control and body weight reduction. Cardiovasc Diabetol. 2022;21(1):169. doi: 10.1186/s12933-022-01604-7.
  4. Shankar A, Sharma A, Vinas A, Chilton RJ. GLP-1 receptor agonists and delayed gastric emptying: implications for invasive cardiac interventions and surgery. Cardiovasc Endocrinol Metab. 2024;14(1):e00321. doi: 10.1097/XCE.0000000000000321.
  5. Reddivari AKR, Mehta P. Gastroparesis. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing. 2024 [updated 2024 Feb 28; cited 2026 Oct 23]. Available from: https://www.ncbi.nlm.nih.gov/books/NBK551528/.
  6. Staller K, Parkman HP, Greer KB, Leiman DA, Zhou MJ, Singh S, et al. AGA Clinical Guidelines Committee. AGA Clinical Practice Guideline on Management of Gastroparesis. Gastroenterology. 2025;169(5):828-861. doi: 10.1053/j.gastro.2025.08.004.
  7. Parkman HP, Rim DS, Anolik JR, Dadparvar S, Maurer AH. Glucagonlike Peptide-1 Receptor Agonists: The Good, the Bad, and the Ugly-Benefits for Glucose Control and Weight Loss with Side Effects of Delaying Gastric Emptying. J Nucl Med Technol. 2024;52(1):3-7. doi: 10.2967/jnmt.123.266800.
  8. Mathew A, Hannoodee H. FRI643 Tirzepatide Associated Partial Small Bowel Obstruction: A Case Report. J Endocr Soc. 2023;7(Suppl 1):bvad114.862. doi: 10.1210/jendso/bvad114.862.
  9. Singhal R, Sachdeva D, Wortman II K, Lall R. Unmasking Semaglutide-Induced Gastroparesis: The Dangers of Rapid Dose Escalation in a Diabetic Patient. Cureus. 2025;17(9):e91679. doi: 10.7759/cureus.91679.
  10. Camilleri M, Parkman HP, Shafi MA, Abell TL, Gerson L. American College of Gastroenterology. Clinical guideline: management of gastroparesis. Am J Gastroenterol. 2013;108(1):18-37; quiz 38. doi: 10.1038/ajg.2012.373.

Published

2026-11-20

How to Cite

1.
Diyora T, Rehman MZU, Ogli AK. Tirzepatide-induced gastroparesis with prolonged recovery. EJCRIM [Internet]. 2026 Nov. 20 [cited 2026 Nov. 22];13. Available from: https://ejcrim.com/index.php/ejcrim/article/view/7493

Most read articles by the same author(s)